Trial Profile
Expanded Access Use of Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2021
Price :
$35
*
At a glance
- Drugs Lixivaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease; Renal pain
- Focus Expanded access; Therapeutic Use
- Sponsors Centessa Pharmaceuticals; Palladio Biosciences
- 08 Oct 2021 Status changed from discontinued to completed.
- 21 Apr 2021 Status changed from active, no longer recruiting to discontinued.
- 28 Jan 2021 Planned End Date changed from 31 Dec 2020 to 28 Feb 2021.